Trials / Completed
CompletedNCT04130191
A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 140 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to compare the number of HAE attacks occuring in persons using lanadelumab with the number of HAE attacks before lanadelumab treatment was started. Data from participants who start the study after 1 March 2021, will be collected for 24 months; data from all other participants (who started the study before 1 March 2021) will be collected for 36 months. Participants will report information in a smartphone application at study start and for the next 3 months and then every 6 months until the study ends; data will also be collected by the study doctor during routine clinic visits
Conditions
Timeline
- Start date
- 2019-12-11
- Primary completion
- 2024-09-09
- Completion
- 2024-09-09
- First posted
- 2019-10-17
- Last updated
- 2025-09-02
Locations
19 sites across 7 countries: Austria, Germany, Israel, Italy, Kuwait, Spain, Switzerland
Source: ClinicalTrials.gov record NCT04130191. Inclusion in this directory is not an endorsement.